Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals

Abstract Antibody–drug conjugates (ADCs) represent a novel class of biopharmaceuticals comprising monoclonal antibodies covalently conjugated to cytotoxic agents via engineered chemical linkers. This combination enables targeted delivery of cytotoxic agents to tumor site through recognizing target a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ruili Wang, Baohui Hu, Ziyu Pan, Chongxia Mo, Xin Zhao, Guojia Liu, Ping Hou, Qi Cui, Zhao Xu, Wenjia Wang, Zhaojin Yu, Lin Zhao, Miao He, Yan Wang, Chen Fu, Minjie Wei, Lifeng Yu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-04-01
Edice:	Journal of Hematology & Oncology
Témata:	Antibody–drug conjugates Monoclonal antibody Cytotoxic agents Linkers Targeted therapy Clinical application
On-line přístup:	https://doi.org/10.1186/s13045-025-01704-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!